Gadolinium Deposition Safety: Seeking the Patient’s Perspective

References

1. 1.↵
   1. Parizel PM,
   2. Degryse HR,
   3. Gheuens J, et al

   . Gadolinium-DOTA enhanced MR imaging of intracranial lesions. J Comput Assist Tomogr 1989;13:378–85 doi:10.1097/00004728-198905000-00002 pmid:2723166

   CrossRefPubMed
2. 2.↵
   1. Aime S,
   2. Caravan P

   . Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 2009;30:1259–67 doi:10.1002/jmri.21969 pmid:19938038

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Knop RH,
   2. Frank JA,
   3. Dwyer AJ, et al

   . Gadolinium cryptelates as MR contrast agents. J Comput Assist Tomogr 1987;11:35–42 doi:10.1097/00004728-198701000-00007 pmid:3805426

   CrossRefPubMed
4. 4.↵
   1. Spinosa DJ,
   2. Kaufmann JA,
   3. Hartwell GD

   . Gadolinium chelates in angiography and interventional radiology: a useful alternative to iodinated contrast media for angiography. Radiology 2002;223:319–25 doi:10.1148/radiol.2232010742 pmid:11997531

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Grobner T

   . Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104–08 doi:10.1093/ndt/gfk062 pmid:16431890

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Cowper SE,
   2. Robin HS,
   3. Steinberg SM, et al

   . Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000–01 doi:10.1016/S0140-6736(00)02694-5 pmid:11041404

   CrossRefPubMedWeb of Science
7. 7.↵
   FDA ALERT. Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging Scans. 2006. https://www.ismrm.org/special/FDA%20gadolinium1206.pdf. Accessed March 4, 2020
8. 8.↵
   1. Kanda T,
   2. Ishii K,
   3. Kawaguchi H, et al

   . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

   CrossRefPubMed
9. 9.↵
   1. Quattrocchi CC,
   2. Mallio CA,
   3. Errante Y, et al

   . Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 2015;50:470–72 doi:10.1097/RLI.0000000000000154 pmid:25756685

   CrossRefPubMed
10. 10.↵
    1. McDonald RJ,
    2. McDonald JS,
    3. Kallmes DF, et al

    . Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology 2017;285:546–54 doi:10.1148/radiol.2017161595 pmid:28653860

    CrossRefPubMed
11. 11.↵
    1. Mallio CA,
    2. Ramalho J,
    3. Quattrocchi CC

    . Impact of brain irradiation, chemotherapy, and presence of primary brain tumors on changes in signal intensity after exposure to gadolinium-based contrast agents. Radiology 2019;290:575–76 doi:10.1148/radiol.2018182349 pmid:30599099

    CrossRefPubMed
12. 12.↵
    1. Errante Y,
    2. Cirimele V,
    3. Mallio CA, et al

    . Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 2014;49:685–90 doi:10.1097/RLI.0000000000000072 pmid:24872007

    CrossRefPubMed
13. 13.↵
    1. Lohrke J,
    2. Frisk AL,
    3. Frenzel T, et al

    . Histology and gadolinium distribution in the rodent brain after the administration of cumulative high doses of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 2017;52:324–33 doi:10.1097/RLI.0000000000000344 pmid:28323657

    CrossRefPubMed
14. 14.↵
    1. Frenzel T,
    2. Lengsfeld P,
    3. Schirmer H, et al

    . Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol 2008;43:817–28 doi:10.1097/RLI.0b013e3181852171 pmid:19002053

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Dekkers IA,
    2. Roos R,
    3. van der Molen AJ

    . Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency. Eur Radiol 2018;28:1579–84 doi:10.1007/s00330-017-5065-8 pmid:29063255

    CrossRefPubMed
16. 16.↵
    1. Bussi S,
    2. Coppo A,
    3. Botteron C, et al

    . Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats. J Magn Reson Imaging 2018;47:746–52 doi:10.1002/jmri.25822 pmid:28730643

    CrossRefPubMed
17. 17.↵
    1. Behzadi AH,
    2. Zhao Y,
    3. Farooq Z, et al

    . Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. Radiology 2018;286:471–82 doi:10.1148/radiol.2017162740 pmid:28846495

    CrossRefPubMed
18. 18.↵
    European Medicines Agency. EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans (21 July 2017). https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents_en-0.pdf. Accessed January 9, 2020
19. 19.↵
    Pharmaceuticals and Medical Devices Agency. Report on the investigation results. Published November 11, 2017. https://www.pmda.go.jp/files/000221379.pdf. Accessed January 9, 2020
20. 20.↵
    1. Shen Z,
    2. Wu A,
    3. Chen X

    . Iron oxide nanoparticle-based contrast agents for magnetic resonance imaging. Mol Pharm 2017;14:1352–64 doi:10.1021/acs.molpharmaceut.6b00839 pmid:27776215

    CrossRefPubMed
21. 21.↵
    1. Amukotuwa SA,
    2. Marks MP,
    3. Zaharchuk G, et al

    . Arterial spin-labeling improves detection of intracranial dural arteriovenous fistulas with MRI. AJNR Am J Neuroradiol 2018;39:669–77 doi:10.3174/ajnr.A5570 pmid:29545245

    Abstract/FREE Full Text
22. 22.↵
    1. Delgado AF,
    2. Delgado AF,
    3. De Luca F, et al

    . Arterial spin-labeling in children with brain tumor: a meta-analysis. AJNR Am J Neuroradiol 2018;39:1536–42 doi:10.3174/ajnr.A5727 pmid:30072368

    Abstract/FREE Full Text
23. 23.↵
    1. Gong E,
    2. Pauly JM,
    3. Wintermark M, et al

    . Deep learning enables reduced gadolinium dose for contrast-enhanced brain MRI. J Magn Reson Imaging 2018;48:330–40 doi:10.1002/jmri.25970 pmid:29437269

    CrossRefPubMed
24. 24.↵
    1. Welk B,
    2. McArthur E,
    3. Morrow SA, et al

    . Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 2016;316:96–98 doi:10.1001/jama.2016.8096 pmid:27380348

    CrossRefPubMed
25. 25.↵
    1. Vymazal J,
    2. Krámská L,
    3. Brožová H, et al

    . Does serial administration of gadolinium-based contrast agents affect patient neurological and neuropsychological status? Fourteen-year follow-up of patients receiving more than fifty contrast administrations. J Magn Reson Imaging 2019 Oct 30. [Epub ahead of print] doi:10.1002/jmri.26948 pmid:31664740

    CrossRefPubMed
26. 26.↵
    1. Eisele P,
    2. Konstandin S,
    3. Szabo K, et al

    . Sodium MRI of T1 high signal intensity in the dentate nucleus due to gadolinium deposition in multiple sclerosis. J Neuroimaging 2017;27:372–75 doi:10.1111/jon.12448 pmid:28569398

    CrossRefPubMed
27. 27.↵
    1. Mallio CA,
    2. Piervincenzi C,
    3. Gianolio E, et al

    . Absence of dentate nucleus resting-state functional connectivity changes in nonneurological patients with gadolinium-related hyperintensity on T1-weighted images. J Magn Reson Imaging 2019;50:445–55 doi:10.1002/jmri.26669 pmid:30681245

    CrossRefPubMed
28. 28.↵
    1. Eisele P,
    2. Szabo K,
    3. Ebert A, et al

    . Diffusion-weighted imaging of the dentate nucleus after repeated application of gadolinium-based contrast agents in multiple sclerosis. Magn Reson Imaging 2019;58:1–5 doi:10.1016/j.mri.2019.01.007 pmid:30630068

    CrossRefPubMed
29. 29.↵
    1. Fingerhut S,
    2. Sperling M,
    3. Holling M, et al

    . Gadolinium-based contrast agents induce gadolinium deposits in cerebral vessel walls, while the neuropil is not affected: an autopsy study. Acta Neuropathol 2018;136:127–38 doi:10.1007/s00401-018-1857-4 pmid:29748901

    CrossRefPubMed
30. 30.↵
    FDA warns that gadolinium-based contrast agents (GBCA) are retained in the body; requires new class warnings. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-gadolinium-based-contrast-agents-gbcas-are-retained-body. Accessed January 9, 2020
31. 31.↵
    ACR–ASNR Position Statement on the use of gadolinium contrast agents. Manual on Contrast Media Version 10.3. https://www.acr.org/-/media/ACR/files/clinical-resources/contrast_media.pdf. Accessed January 9, 2020
32. 32.↵
    1. Gulani V,
    2. Calamante F,
    3. Shellock FG, et al

    ; International Society for Magnetic Resonance in Medicine. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol 2017;16:564–70 doi:10.1016/S1474-4422(17)30158-8 pmid:28653648

    CrossRefPubMed
33. 33.↵
    1. Quattrocchi CC,
    2. Ramalho J,
    3. van der Molen AJ, et al

    ; GREC, European Gadolinium Retention Evaluation Consortium and the ESNR, European Society of Neuroradiology. Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement. Eur Radiol 2019;29:3959–67 doi:10.1007/s00330-018-5803-6 pmid:30413951

    CrossRefPubMed
34. 34.↵
    1. Darrah TH,
    2. Prutsman-Pfeiffer JJ,
    3. Poreda RJ, et al

    . Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 2009;1:479–88 doi:10.1039/b905145g pmid:21305156

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Roberts DR,
    2. Lindhorst SM,
    3. Welsh CT, et al

    . High levels of gadolinium deposition in the skin of a patient with normal renal function. Invest Radiol 2016;51:280–89 doi:10.1097/RLI.0000000000000266 pmid:26953564

    CrossRefPubMed
36. 36.↵
    1. Maximova N,
    2. Gregori M,
    3. Zennaro F, et al

    . Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients. Radiology 2016;281:418–26 doi:10.1148/radiol.2016152846 pmid:27276243

    CrossRefPubMed
37. 37.↵
    1. Mallio CA,
    2. Lo Vullo G,
    3. Messina L, et al

    . Increased T1 signal intensity of the anterior pituitary gland on unenhanced magnetic resonance images after chronic exposure to gadodiamide. Invest Radiol 2020;55:25–29 doi:10.1097/RLI.0000000000000604 pmid:31498162

    CrossRefPubMed
38. 38.↵
    1. Semelka RC,
    2. Ramalho J,
    3. Vakharia A, et al

    . Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magn Reson Imaging 2016;34:1383–90 doi:10.1016/j.mri.2016.07.016 pmid:27530966

    CrossRefPubMed
39. 39.↵
    1. Parillo M,
    2. Sapienza M,
    3. Arpaia F, et al

    . A structured survey on adverse events occurring within 24 hours after intravenous exposure to gadodiamide or gadoterate meglumine: a controlled prospective comparison study. Invest Radiol 2019;54:191–97 doi:10.1097/RLI.0000000000000528 pmid:30379729

    CrossRefPubMed